Brigitte Ederer, who studied economics, held various top management positions at Siemens from 2001 to 2013. Prior to that, she was a politician from 1983 to 2001, and during this time she was a member of the Austrian Parliament, Secretary of State for European Affairs and Finance City Councillor in Vienna. Brigitte Ederer is also a member of several supervisory boards, including Boehringer Ingelheim Austria RCV GmbH, Infineon Technologies Austria AG and Schoeller Bleckmann Oilfield Equipment AG.
The offer period for the initial public offering of Marinomed on the Vienna Stock Exchange is currently running. Investors can sign up for new Marinomed shares in the price range of 75-90 Euro per share until 29 November 2018. The final offer price will be determined on the basis of the bookbuilding procedure and is expected to be published on 29 November 2018. The first day of listing is scheduled for 4 December 2018.
About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com.